Winbond Pharmaceutical Co., Ltd. located in Chongqing High-tech Development Zone of Chongqing, is a registered capital of 132 million, more than 600 employees and total assets of several hundred million high-tech joint-stock pharmaceutical companies.

Winbond March 2000, Winbond was awarded the National Science and Technology pharmaceutical "National Key High-tech Enterprise"; April 2000, Chongqing City, the first full GMP plant certified by the State enterprises; in 2003 won the "National Labor Award"; for five consecutive years was named "top fifty industrial enterprises in Chongqing"; the seventh consecutive year as "outstanding enterprises in Chongqing High-tech Development Zone"; June 25, 2004, the company listed in the Shenzhen Stock Exchange.

as a national key high-tech enterprise Winbond Winbond pharmaceutical Since its inception, to look for the "scientific career" goals, the research and development of new drugs settle down as a fundamental business, high technology, high quality, professional challenges as the enterprise's core competitiveness. After ten years of unremitting efforts, Winbond in the dermatology field, the field of TB treatment and establish a good corporate brand image, has become a development, production and sales of professional manufacturers of retinoic acid-type drugs.

Winbond pharmaceutical pharmaceutical industry related to the diversification of the development process, the implementation of the pharmaceutical industry as the basis, as a link chain, market-leading , technology support, to the basic talent, product management and capital management as the basis of the high level of development strategy, build a core competitiveness of enterprises. Currently, Winbond Pharmaceutical Holdings and shares have been the way to get involved in tourism, energy, pharmaceuticals, investing in the construction of natural Hanbang Pharmaceutical Co., Ltd. Chongqing, Chongqing T & H Travel Co., Ltd., Chongqing limited Winbond Hoteliers , Chongqing Winbond Energy Technology Co., Ltd., thereby taking the company "multiple concentric development of the future" strategic pace.